Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

Abstract

The present study investigated the interaction between c-erbB2 overexpression and the response to first-line endocrine therapy in patients with advanced breast cancer. The primary tumours of 241 patients who were treated at first relapse with endocrine therapy were assessed for overexpression of c-erbB2 by immunohistochemistry. c-erbB2 was overexpressed in 76 (32%) of primary breast cancers and did not correlate with any other prognostic factor. The overall response to treatment and time to progression were significantly lower in patients with c-erbB2-positive tumours compared to those that were c-erbB2-negative (38% vs 56%, P = 0.02; and 4.1 months vs 8.7 months, P < 0.001, respectively). In multivariate analysis, c-erbB2 status was the most significant predictive factor for a short time to progression (P = 0.0009). In patients with ER-positive primary tumours treated at relapse with tamoxifen (n = 170), overexpression of c-erbB2 was associated with a significantly shorter time to progression (5.5 months vs 11.2 months, P < 0.001). In conclusion, overexpression of c-erbB2 in the primary tumour is an independent marker of relative resistance to first-line endocrine therapy in patients with advanced breast cancer. In patients with ER-positive primary tumours, the overexpression of c-erbB2 defines a subgroup less likely to respond to endocrine therapy.

References 31

1. 1.

   Allred D. C., Clark G. M., Tandon A. K., Molina R., Tormey D. C., Osborne C. K., Gilchrist K. W., Mansour E. G., Abeloff M., Eudey L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10(4):599-605.

   Not in our library10.1200/jco.1992.10.4.599

2. 2.

   Archer S. G., Eliopoulos A., Spandidos D., Barnes D., Ellis I. O., Blamey R. W., Nicholson R. I., Robertson J. F. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995;72(5):1259-1266.

   Not in our library10.1038/bjc.1995.497

3. 3.
   An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma · 1988

   No notice
4. 4.

   Barnes D. M., Millis R. R., Beex L. V., Thorpe S. M., Leake R. E. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer. 1998;34(11):1677-1682.

   Not in our library10.1016/s0959-8049(98)00149-x

5. 5.

   Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14(3):737-744.

   Not in our library10.1200/jco.1996.14.3.737

6. 6.

   Borg A., Baldetorp B., Fernö M., Killander D., Olsson H., Rydén S., Sigurdsson H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994;81(2):137-144.

   Not in our library10.1016/0304-3835(94)90194-5

7. 7.

   Ciocca D. R., Fujimura F. K., Tandon A. K., Clark G. M., Mark C., Lee-Chen G. J., Pounds G. W., Vendely P., Owens M. A., Pandian M. R. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992;84(16):1279-1282.

   Not in our library10.1093/jnci/84.16.1279

8. 8.

   Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-1139.

   Not in our library10.1126/science.2999974

9. 9.

   Gusterson B. A., Gelber R. D., Goldhirsch A., Price K. N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992;10(7):1049-1056.

   Not in our library10.1200/jco.1992.10.7.1049

10. 10.

    Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977;39(3):1289-1294.

    Not in our library10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f

11. 11.

    Holdaway I. M., Mason B. H., Gibbs E. E., Rajasoorya C., Lethaby A., Hopkins K. D., Evans M. C., Lim T., Schooler B. Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer. Breast Cancer Res Treat. 1997;42(1):15-22.

    Not in our library10.1023/a:1005743626105

12. 12.

    Karunagaran D., Tzahar E., Beerli R. R., Chen X., Graus-Porta D., Ratzkin B. J., Seger R., Hynes N. E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996;15(2):254-264.

    Not in our library

13. 13.

    Kath R., Höffken K., Otte C., Metz K., Scheulen M. E., Hülskamp F., Seeber S. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol. 1993;4(7):585-590.

    Not in our library10.1093/oxfordjournals.annonc.a058593

14. 14.

    Kern F. G., Cheville A. L., Liu Y. L. Growth factor receptors and the progression of breast cancer. Semin Cancer Biol. 1990;1(5):317-328.

    Not in our library

15. 15.

    Kuukasjärvi T., Kononen J., Helin H., Holli K., Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14(9):2584-2589.

    Not in our library10.1200/jco.1996.14.9.2584

16. 16.

    Leitzel K., Teramoto Y., Konrad K., Chinchilli V. M., Volas G., Grossberg H., Harvey H., Demers L., Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995;13(5):1129-1135.

    Not in our library10.1200/jco.1995.13.5.1129

17. 17.

    Leitzel K., Teramoto Y., Sampson E., Mauceri J., Langton B. C., Demers L., Podczaski E., Harvey H., Shambaugh S., Volas G. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol. 1992;10(9):1436-1443.

    Not in our library10.1200/jco.1992.10.9.1436

18. 18.

    Newby J. C., Johnston S. R., Smith I. E., Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997;3(9):1643-1651.

    Not in our library

19. 19.

    Niehans G. A., Singleton T. P., Dykoski D., Kiang D. T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst. 1993;85(15):1230-1235.

    Not in our library10.1093/jnci/85.15.1230

20. 20.

    O'Malley F. P., Saad Z., Kerkvliet N., Doig G., Stitt L., Ainsworth P., Hundal H., Chambers A. F., Turnbull D. I., Bramwell V. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Hum Pathol. 1996;27(9):955-963.

    Not in our library10.1016/s0046-8177(96)90224-5

21. 21.

    Pietras R. J., Arboleda J., Reese D. M., Wongvipat N., Pegram M. D., Ramos L., Gorman C. M., Parker M. G., Sliwkowski M. X., Slamon D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10(12):2435-2446.

    Not in our library

22. 22.

    Press M. F., Bernstein L., Thomas P. A., Meisner L. F., Zhou J. Y., Ma Y., Hung G., Robinson R. A., Harris C., El-Naggar A. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15(8):2894-2904.

    Not in our library10.1200/jco.1997.15.8.2894

23. 23.

    Press M. F., Pike M. C., Chazin V. R., Hung G., Udove J. A., Markowicz M., Danyluk J., Godolphin W., Sliwkowski M., Akita R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53(20):4960-4970.

    Not in our library

24. 24.

    Ravdin P. M., Green S., Dorr T. M., McGuire W. L., Fabian C., Pugh R. P., Carter R. D., Rivkin S. E., Borst J. R., Belt R. J. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1284-1291.

    Not in our library10.1200/jco.1992.10.8.1284

25. 25.

    Rubens R. D., Hayward J. L. Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer. 1980;46(12 Suppl):2922-2924.

    Not in our library10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d

26. 26.

    Saceda M., Grunt T. W., Colomer R., Lippman M. E., Lupu R., Martin M. B. Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology. 1996;137(10):4322-4330.

    Not in our library10.1210/endo.137.10.8828492

27. 27.

    Sjögren S., Inganäs M., Lindgren A., Holmberg L., Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16(2):462-469.

    Not in our library10.1200/jco.1998.16.2.462

28. 28.

    Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.

    Not in our library10.1126/science.3798106

29. 29.

    Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.

    Not in our library10.1126/science.2470152

30. 30.
    Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer · 1992

    No notice
31. 31.

    Yamauchi H., O'Neill A., Gelman R., Carney W., Tenney D. Y., Hösch S., Hayes D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997;15(7):2518-2525.

    Not in our library10.1200/jco.1997.15.7.2518

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.